Cidara Therapeutics Stock Performance
| CDTX Stock | USD 221.38 0.06 0.03% |
Cidara Therapeutics has a performance score of 19 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.4, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cidara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cidara Therapeutics is expected to be smaller as well. Cidara Therapeutics right now shows a risk of 0.18%. Please confirm Cidara Therapeutics potential upside, and the relationship between the jensen alpha and accumulation distribution , to decide if Cidara Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Cidara Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
Year To Date Return 0.16 | Ten Year Return 7.05 | All Time Return (30.82) |
| Begin Period Cash Flow | 35.8 M | |
| Total Cashflows From Investing Activities | -129 K |
Cidara Therapeutics Relative Risk vs. Return Landscape
If you would invest 21,791 in Cidara Therapeutics on November 17, 2025 and sell it today you would earn a total of 347.00 from holding Cidara Therapeutics or generate 1.59% return on investment over 90 days. Cidara Therapeutics is currently generating 0.0453% in daily expected returns and assumes 0.1821% risk (volatility on return distribution) over the 90 days horizon. In different words, 1% of stocks are less volatile than Cidara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cidara Therapeutics Target Price Odds to finish over Current Price
The tendency of Cidara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 221.38 | 90 days | 221.38 | about 17.02 |
Based on a normal probability distribution, the odds of Cidara Therapeutics to move above the current price in 90 days from now is about 17.02 (This Cidara Therapeutics probability density function shows the probability of Cidara Stock to fall within a particular range of prices over 90 days) .
Cidara Therapeutics Price Density |
| Price |
Predictive Modules for Cidara Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cidara Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cidara Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cidara Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cidara Therapeutics is not an exception. The market had few large corrections towards the Cidara Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cidara Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cidara Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.74 | |
β | Beta against Dow Jones | 0.40 | |
σ | Overall volatility | 58.80 | |
Ir | Information ratio | 0.13 |
Cidara Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cidara Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cidara Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cidara Therapeutics is not yet fully synchronised with the market data | |
| The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (169.83 M) with loss before overhead, payroll, taxes, and interest of (131.82 M). | |
| Cidara Therapeutics currently holds about 53.08 M in cash with (176.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Cidara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies |
Cidara Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cidara Stock often depends not only on the future outlook of the current and potential Cidara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cidara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.3 M | |
| Cash And Short Term Investments | 189.8 M |
Cidara Therapeutics Fundamentals Growth
Cidara Stock prices reflect investors' perceptions of the future prospects and financial health of Cidara Therapeutics, and Cidara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cidara Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 6.54 B | ||||
| Shares Outstanding | 31.45 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 16.48 X | ||||
| Price To Sales | 4,541 X | ||||
| Revenue | 1.27 M | ||||
| Gross Profit | (131.82 M) | ||||
| EBITDA | (175.87 M) | ||||
| Net Income | (169.83 M) | ||||
| Cash And Equivalents | 53.08 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 3.58 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | 14.40 X | ||||
| Cash Flow From Operations | (176.53 M) | ||||
| Earnings Per Share | (11.20) X | ||||
| Market Capitalization | 6.96 B | ||||
| Total Asset | 214.8 M | ||||
| Retained Earnings | (611.26 M) | ||||
| Working Capital | 161.18 M | ||||
| Current Asset | 108.22 M | ||||
| Current Liabilities | 5.97 M | ||||
About Cidara Therapeutics Performance
Evaluating Cidara Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cidara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cidara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 54.48 | 57.20 | |
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.96) | (0.91) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.20) | (1.14) |
Things to note about Cidara Therapeutics performance evaluation
Checking the ongoing alerts about Cidara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cidara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cidara Therapeutics is not yet fully synchronised with the market data | |
| The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (169.83 M) with loss before overhead, payroll, taxes, and interest of (131.82 M). | |
| Cidara Therapeutics currently holds about 53.08 M in cash with (176.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Cidara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cidara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cidara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cidara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cidara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cidara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cidara Therapeutics' stock. These opinions can provide insight into Cidara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.